After myocardial infarction. Supplementary treatment as part of secondary prevention after myocardial infarction, including other standard medications (eg statins, antiplatelet drugs, β-blockers, ACE inhibitors).hypertriglyceridemia. In people with endogenous hypertriglyceridemia as a supplement to the diet when the use of diet alone is not enough to achieve a sufficient therapeutic response: type IV - monotherapy or type IIb / III - in combination with statins, if the reduction in triglycerides is insufficient.
Composition:
1 capsule contains 1000 mg of ethyl esters of omega-3, including: 460 mg of eicosapentaenoic acid ethyl ester (EPA) and 380 mg of docosahexaenoic acid ethyl ester (DHA).
Action:
Essential polyunsaturated fatty acids from the omega-3 family. EPA and DHA are poorly utilized substrates of enzymes responsible for triglyceride synthesis and inhibit the esterification of other fatty acids. They reduce the concentration of VLDL lipoproteins and triglycerides in the blood. The drug increases the level of LDL cholesterol in some patients with hypertriglyceridemia. The increase in HDL cholesterol is low. During the treatment with the preparation, the production of thromboxane A decreases2 and for a slight extension of the bleeding time. Pharmacokinetic studies have shown that full hydrolysis of the ethyl ester occurs with a satisfactory level of absorption of EPA and DHA and their incorporation into plasma phospholipids and cholesterol esters.
Contraindications:
Hypersensitivity to the active substance, soya or any of the excipients.
Precautions:
It is not advisable to use the preparation in exogenous hypertriglyceridemia (type 1 hyperchylomicronemia). Experience in the use of the preparation in secondary endogenous hypertriglyceridemia (especially in the course of uncontrolled diabetes) is limited. There is no experience with administering the drug in people with hypertriglyceridemia in combination with fibrates. There is no information on the use of the preparation in children and adolescents (not recommended), in people aged> 70 years, in patients with hepatic impairment. Only limited information is available on the use of the drug in patients with renal insufficiency. It may cause moderate prolongation of bleeding time - be cautious, especially at high doses (ie 4 capsules / day) in patients taking anticoagulants (regular check-ups and adjustments if necessary) and in patients at high risk of haemorrhage . The levels of aminotransferases (AST and ALAT) should be monitored regularly in patients with any symptoms of liver failure (especially when using high doses, ie 4 capsules / day).
Pregnancy and lactation:
The preparation should not be used during pregnancy unless clearly necessary. Do not use during breast-feeding.
Orally. Secondary prevention after myocardial infarction: 1 capsule per day. Hypertriglyceridemia: 2 capsules per day at the beginning of treatment; in the absence of a sufficient therapeutic response, the dose can be increased to 4 capsules per day. The preparation should be taken during a meal.
(C)
